Mr. Chair, just to reinforce what my colleague has said, one of the biggest lessons learned was to have early communication and notification—this is what we heard from our medical community and from the provinces and territories—so that they could plan ahead and know how long to plan for. That was one of the biggest lessons learned. It was in the invaluable advice we got from the lessons learned report last year. The communications protocol to give virtually instantaneous notice of the fact that the NRU is going to be down for a certain length of time was instrumental in getting this contingency plan going.
We also have been working very hard over the last year with the medical professionals and with the provinces and territories to have these alternatives in place, should we need them, and all the regulatory approvals.
My job as the ADM of the health products and food branch is to make sure that whatever Canadians are using by way of health products is safe and comes from a quality place and actually does what it's supposed to do. Any time there is a new source of moly-99, or new generators, or a new condition for which you're going to use the same medication, our scientists look at it and make sure the approvals are in place. We've been working on this, and now it's unfolding and these measures are out there.
As I said concerning the supply chain, with the two main suppliers having diversified their supply chains and with the international conversations that are going on, there is real hope about boosting the supply chain this time around that wasn't there last time.